Prescription medicine

Atoltivimab and maftivimab and odesivimab Brand names: Inmazeb

Atoltivimab and maftivimab and odesivimab (Inmazeb) is a prescription medicine with an FDA approval on record since 2020. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the atoltivimab and maftivimab and odesivimab FDA label on DailyMed (effective December 15, 2025, Regeneron Pharmaceuticals, Inc.); the BLA 761169 record on Drugs@FDA; every atoltivimab and maftivimab and odesivimab label on DailyMed.

Highlights of the record

FDA label of December 15, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection [see Dosage and Administration (2.2), and Clinical Studies (14) ].

Forms and strengths

241.7 mg/14.5ml / 241.7 mg/14.5ml / 241.7 mg/14.5ml
483.3 mg/14.5ml / 483.3 mg/14.5ml / 483.3 mg/14.5ml

Injection (solution).

On the market

Earliest approval on file: October 14, 2020 Inmazeb, Regeneron Pharmaceuticals; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded

What is atoltivimab and maftivimab and odesivimab used for?

From the label: indications and usage
INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection [see Dosage and Administration (2.2), and Clinical Studies (14) ]. INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. […]

Source: FDA drug label (Inmazeb), Regeneron Pharmaceuticals, Inc., effective December 15, 2025 (SPL set 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa), via openFDA; the full label on DailyMed

Is there a generic for atoltivimab and maftivimab and odesivimab (Inmazeb)?

No generic atoltivimab and maftivimab and odesivimab is approved (Drugs@FDA, October 8, 2026).

2020 earliest approval on file

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What next?

Check an interaction: what two or more labels say about each other